Kornimate/medical-research-clean huggingface dataset:
efficacy of dry needling treatment in myofascial pain syndrome

Conditions: Trigger Point Pain, Myofascial

Summary: the aim of this study is to investigate the short and long-term effects of dry-needling of participants with trigger points in the upper trapezius muscle. 64 participants who diagnosed with myofascial pain syndrome will be included in the study. all participants will have trigger points in the upper trapezius muscles. they are randomised into two groups: dry needling (n=32) and exercise group (n=32). ultrasonographic evaluation of trigger points (diameter, circumference and area), pain intensity and neck disability will be evaluated as primary outcome. active cervical range of motion will be evaluated as secondary outcome.

objective: the aim of this study is to investigate the short and long-term effects of dry-needling of participants with trigger points in the upper trapezius muscle. methods: 64 participants who diagnosed with myofascial pain syndrome will be included in the study. all participants will have trigger points in the upper trapezius muscles. they are randomised into two groups: dry needling (n=32) and exercise group (n=32). ultrasonographic evaluation of trigger points (diameter, circumference and area), pain intensity and neck disability will be evaluated as primary outcome. active cervical range of motion will be evaluated as secondary outcome. all treatments will be applied by an investigator and a different blinded investigator will evaluated all participants. numerical rating scale will be used for evaluating pain intensity and neck disability index will be used for evaluating neck disability. dry-needling treatment will be applied once a week for three weeks. servical stretching exercises are given to all participants. (20 repetitions in one session and 2 sessions in a day, three days a week.) all participants will be evaluated before treatment, after treatment (at 3rd week) and at 3 month follow-ups.

Eligibility criteria:
inclusion criteria: * trigger points in the upper trapezius muscle * 18-45 years old * no treatment in three months for myofascial pain syndrome (mps) * accept to participate treatment program exclusion criteria: * already treated in 3 months for mps * below 18 years and above 45 years old * no acceptance to participate the trial

Keywords: trigger point dry-needling ultrasonography pain intensity neck disability
adolescent transition to adult care for hiv-infected adolescents in kenya

Conditions: Adolescent Behavior; HIV; Transition; Adolescent Development; Disclosure

Summary: this study evaluates an adolescent transition package (atp) to support hiv infected adolescents transitioning form pediatric/adolescent care to adult care. ten clinics will receive the intervention and 10 will receive standard of care transition services.

the adolescent transition package (atp) will include two components. the validated namibia comic book for disclosure (to be used with children over 10 years of age) and transition booklet "taking charge" developed by stakeholders in kenya. the disclosure tool includes a cartoon book, readiness and tracking tools used in clinic and health care worker training material. the intervention progresses from incomplete to complete disclosure using a narrative about soldiers fighting the battle of infection as the rationale for taking medicine. this tool has been validated for use in namibia. the adapted transition toolkit includes a transition booklet, tracking tools to be used by health care workers and a readiness assessment checklist to be completed by study staff. the booklet has 4 chapters addressing key areas to support adolescents gain the knowledge and skills they need in adult care. the 4 chapters are: hiv treatment literacy, self management, communication and support.

Eligibility criteria:
inclusion criteria: * facility leadership is willing to implement the intervention exclusion criteria: * clinics already actively using transition or disclosure tools
characterization and causative factors of negative dysphotopsia

Conditions: Pseudoaphakia

Summary: the present study is designed as an exploratory study, seeking to investigate the correlation of patient complaints to subjective or objective measurement methods. better understanding of causative factors of negative dysphotopsia will improve detection and maybe prediction of this optical phenomenon.


Eligibility criteria:
inclusion criteria: * pseudophakic * recurrently and persistently reporting about negative dysphotopsia * age 21 and older * written informed consent prior to entering the study exclusion criteria: * relevant ophthalmic diseases such as: glaucoma, (previous) traumatic cataract, corneal scars, age-related macular degeneration and other pathologies resulting in visual field defects * pregnancy
molecular determinants of acquired clinical resistance to crizotinib in non-small cell lung cancer harboring a translocation or inversion event involving the alk gene locus

Conditions: Lung Cancer

Summary: the purpose of this study is to try to learn more about how small molecule kinase inhibitor medications work in treating lung cancer. crizotinib (pf-02341066) is a drug that has been shown to shrink tumors in some patients with lung cancer. while the investigators know how this drug works to stop the growth of tumors that depend on change in the gene named alk (also called eml4-alk), the investigators do not know why the drug stops working. the investigators would like to examine the tumor to help us better understand why crizotinib has stopped working as well as it once did. the tumor will be examined with multiple tests to look for the reason that crizotinib stopped working.


Eligibility criteria:
inclusion criteria: * ≥18 years of age * histologically proven diagnosis of nsclc at mskcc tumor positive for a translocation or inversion event involving the alk gene locus * clinical response to treatment with crizotinib as defined by either: radiographic partial or complete response defined by recist or who or: radiographic stable disease for at least 8 weeks * radiographic progression of disease amenable to biopsy while on treatment with crizotinib as defined by recist or who * signed informed consent exclusion criteria: * deemed by their treating physician to be medically unfit for biopsy * women who are pregnant or breast-feeding

Keywords: core biopsy resistance to crizotinib non-small cell lung cancer 11-014
prognostic value of myocardial fibrosis quantified using cmr in patient with dilated cardiomyopathy

Conditions: Cardiomyopathy, Dilated

Summary: : fibrosis, in general, is a scarring process, which is characterized by fibroblast accumulation and excess deposition of extracellular matrix (ecm) proteins, which leads to distorted organ architecture and function. the contribution of fibrogenesis to impaired cardiac function is increasingly recognized. the fibrotic ecm causes increased stiffness and induces pathological signaling within cardiomyocytes resulting in progressive cardiac failure. also, the excessive ecm impairs mechano-electric coupling of cardiomyocytes and increases the risk of arrhythmias. but today patient treatment and prognosis is based on ejection fraction quantification, qrs duration, and symptoms. hypothesis: the increased level of fibrosis quantified using t1 mapping technique, compared with normal value, is of prognostic value in patient with dilated cardiomyopathies under optimal treatment. methods: 330 patients are planned to be included and followed for 2 years


Eligibility criteria:
inclusion criteria: * patient with dilated cardiomyopathy and typical symptoms of cardiac insufficiency at the time of the diagnosis: oedemas of lower limbs, dyspnoea, asthenia. * and of a reduction in the fraction of ventricular ejection left (awkward) 45 % measured in echocardiography ( modified simpson biplane) and associated with a volume télédiastolic volume superior to the normal in echocardiography: \> 90ml / m2 ( modified simpson biplane). exclusion criteria: * patients to whom the dysfunction vg is secondary or in a secondary overload of pressures in a hta or a severe valvulopathie is in a coronary infringement(achievement), proved by histories of infarct or gestures(movements) of revascularisation (bypass(decking), stent) and or coronary hurts at least bi tronculaires significant the severity of which can explain the ventriculaire failure.
the effect on envelope of motion in asymptomatic bruxers

Conditions: Tooth Wear; Bruxism

Summary: investigating the effect of botulinum neurotoxin on the jaw-neck envelope of motion.

research subjects will be allocated to placebo or botulinum neurotoxin intervention. a control group will not receive any intervention. the intervention will be administered at three separate sessions with 12 weeks in between. prior to intervention, and 6 months after last intervention the jaw-neck envelope of motion will be studied using 3d optoelectronic recording systems.

Eligibility criteria:
inclusion criteria: • tooth wear into dentin. exclusion criteria: * no temporomandibular pathology. * no drugs affecting the central nervous system. * no conditions affecting muscles or central nervous system.
nerveblocks for persistent pain after breast cancer surgery

Conditions: Pain; Neuropathic Pain; Breast Cancer

Summary: persistent pain after breast cancer surgery (ppbcs) affects 25-60% of breast cancer survivors and nerve damage has been implicated as the cause of this neuropathic pain condition. local anaesthetic blockade of tenderpoints and the intercostobrachial nerve (icbn) could provide clues to pathophysiological mechanisms as well as aiding diagnosis and treatment of ppbcs but has never been attempted. the aims of this study is to examine clinical effect of ultrasound guided blockades of the icbn and tenderpoints of pain.


Eligibility criteria:
inclusion criteria: * at least 1 year after surgery for breast cancer * women aged 18 or over * suffering from persistent pain in the breast, side of chest, axilla or arm (nrs 4 or over) exclusion criteria: * previous cosmetic surgery * bilateral cancer * pregnant or lactating * other disease in the nervous system * in treatment for psychiatric disease * unable to understand danish * unable to give informed concent

Keywords: postoperative
exploratory study of tac-302 in detrusor underactivity patients with overactive bladder.

Conditions: Detrusor Underactivity; Overactive Bladder

Summary: the purpose of this study is to evaluate the efficacy and safety of tac-302 in detrusor underactivity patients with overactive bladder.

the main purpose of this study is to assess the efficacy of tac-302 for 12 weeks in detrusor underactivity patients with overactive bladder by measuring the following parameters of pressure-flow study. * male; bladder contractility index (bci) * female; projected isovolumetric pressure (pip) 1

Eligibility criteria:
key inclusion criteria: * to have lower urinary tract symptoms for at least 12 weeks prior to study entry * to have at least 1 urinary urgency episodes per day, and diurnal urinary frequency of 8 or more per day. * to meet the detrusor underactivity criteria by urodynamic study key exclusion criteria: * neurogenic bladder by the central nervous system diseases. * stageiii or more cystocele of pelvic organ prolapse quantification system (women) * prostate volume ≥30ml (men) * any symptoms of urinary tract infection (uti)

Keywords: lower urinary tract symptoms
a multicenter cancer biospecimen collection study

Conditions: Cancer of Head and Neck; Lung Cancer, Nonsmall Cell; Small-cell Lung Cancer; Urothelial Carcinoma; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Colorectal Cancer

Summary: this study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. these specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

this study will establish a prospective cohort of pre-treatment tumor specimens with correlated de-identified clinical and demographic data and tissue histology from cancer patients who are undergoing treatment with pd-1/pd-l1 inhibitors. patients who have undergone pre-anti-pd-1/pd-l1-treatment tumor biopsy or who are scheduled for tumor biopsy prior to anti-pd-1/pd-l1 treatment will be enrolled. the study will not require a study-specific tumor biopsy; any biopsies taken prior to treatment as part of standard of care are eligible for this study. biopsies must not have been taken after immunotherapy treatment began. participants will be asked to provide their consent for the potential use of their biospecimens in subsequent studies for the development and validation of a diagnostic test.

Eligibility criteria:
inclusion criteria: 1. subject must have a disease of interest. specifically, subject must have one of: 1. head and neck squamous cell carcinoma (hnscc) 2. non-small-cell lung cancer (nsclc) 3. small cell lung cancer (sclc) 4. urothelial carcinoma (ucc) 5. gastric or gastroesophageal junction adenocarcinoma 6. cervical cancer 7. esophageal squamous cell carcinoma (escc) 8. triple-negative breast cancer (tnbc) 9. hepatocellular carcinoma (hcc) 10. renal cell carcinoma (rcc) 11. colorectal cancer (crc) 2. subject must have received, or be scheduled to receive, at least one dose of anti-pd-1/pd-l1 immunotherapy for treatment of their cancer. 3. subject must have had, or will have, a tumor biopsy prior to treatment with anti-pd-1/pd-l1 immunotherapy. 4. subject must have undergone, or will undergo, medical imaging (e.g. ct or mri) of the tumor prior to treatment with anti-pd-1/pd-l1 immunotherapy. 5. willing to provide electronic informed consent per irb-approved protocol. 6. able to speak, read, and comprehend english fluently. 7. subject is 18 years of age or older. 8. subjects must have sufficient tissue available to fulfill the specimen requirements of the study. exclusion criteria: 1. inability or unwillingness to provide informed consent. 2. subject who does/did not have one of the cancers listed above (other histologies). 3. subject has already participated in this trial.
pilot study evaluating doxercalciferol replacement therapy in kidney transplant recipients

Conditions: Chronic Kidney Disease; Kidney Transplantation

Summary: people with kidney transplants often develop bone disease. one reason for bone disease may be overactivity of a gland in the neck called the parathyroid gland. overactivity of the parathyroid gland may be caused by lack of vitamin d in the body. it has recently been discovered that many patients with kidney transplants have low vitamin d levels. the investigators are examining the effects of doxercalciferol on parathyroid hormone levels, proteinuria and bone turnover markers in people who have had a kidney transplant.

people with kidney transplants often develop bone disease. one reason for bone disease may be overactivity of a gland in the neck called the parathyroid gland. overactivity of the parathyroid gland may be caused by lack of vitamin d in the body. it has recently been discovered that many patients with kidney transplants have low vitamin d levels. 25-oh vitamin d3 is now recommended to treat kidney transplant patients with low vitamin d levels but it may not be enough to treat the parathyroid problems and bone disease. doxercalciferol is a form of vitamin d that has been used to treat bone disease and parathyroid problems in dialysis patients but has not yet been studied in patients with kidney transplants. we are interested in seeing whether doxercalciferol given together with 25-oh vitamin d3 will be a better treatment for the overactive parathyroid gland and bone disease than 25-oh vitamin d3 alone in patients with kidney transplants.

Eligibility criteria:
inclusion criteria: * adults of both genders between the ages of 18 and 65. * kidney transplant at least 1 year prior to enrollment * creatinine value of \ 0.5 within the past 3 months * proteinuria of 500 mg/24 hours or a protein/creatinine ratio of 0.5 or greater * hypovitaminosis d, as defined by a 25-oh vitamin d value of \<25 ng/ml * intact pth value between 150 and 600 pg/ml exclusion criteria: * history of parathyroidectomy * history of prior intolerance to vitamin d therapy (not including hypercalcemia) * history of biopsy proven acute rejection over the 3 months preceding enrollment * recent (over the past month) addition of an ace inhibitor or angiotensin - * receptor blocking agent - patients who have been on a stable dose are acceptable * current use of active vitamin d supplement (patients in whom therapy has been discontinued more than 1 month prior to enrollment are acceptable) * postmenopausal woman or women receiving hormone replacement therapy

Keywords: kidney transplantation kidney transplant recipients
translation of district sun safe policies to schools

Conditions: Sun Safety; Sun Safe Schools; Prevention of Skin Cancer

Summary: the purpose of the translation of district sun safe policies to schools study was to test whether schools need assistance to facilitate the implementation of school district board-approved sun safety policies by individual elementary schools. the intervention is expected to produce a change in practices at the school level and to improve the sun safety behavior of children attending the intervention schools compared to control schools. a group of 40 school districts in southern california that adopted board policy 5141.7 for sun safety provided 118 schools that were randomized to a intervention condition or to an attention control condition. the primary outcome is change in school-level sun safety practices based on 10 centers for disease control and prevention (cdc) categories for policy change (i.e., sunscreen use, uv protective clothing, hats, student education, teacher education, provision of shade, scheduling to avoid peak uv exposure, parent outreach, resource allocation for sun safety, and an accountability system). this primary outcome was assessed by a survey of the principal and one teacher at each school (n=118 principals and 113 teachers at pretest). parents (n=1770 at pretest) of children attending the schools completed a self-report measure assessing the secondary outcomes of change in individual-level sun safety behavior of their elementary school aged children and number of communications received from the school regarding sun safety. assessment of principals, teachers and parents occurred at pretest, just prior to randomization, and at a posttest 20-months after the pretest. one parent teacher association (pta) representative per school was contacted to assess pta involvement in intervention activities related to sun safety. the primary hypothesis was stated for the effectiveness of the intervention condition at increasing school-level sun safety practices consistent with the sun safety policies of the school districts and read, h1: at follow-up, a greater percentage of schools in the intervention condition will implement at least one component of the school district sun safety policy compared to schools randomized to the attention-control condition.


Eligibility criteria:
inclusion criteria: * school districts in california with school board policy 5141.7 available online, and with at least one elementary school. exclusion criteria: * schools districts that do not have school board policy 5141.7 online, or do not have any elementary schools
adaptive sports for individuals with a physical disability : effect among stroke survivors

Conditions: Stroke

Summary: the objective of the study is to evaluate the effect of engaging in adaptive sports for individuals who have had a stroke. the study is cross-sectional, participants with stroke will be recruited and divided into two groups: the first group composed of individuals with stroke who regularly participate in adaptive sports; and the second of individuals with stroke who do not regularly participate in adaptive sports. the two groups will have to be similar in terms of demographic variables (age, gender, time since beginning of stroke). a series of parameters will be tested, on one occasion for each participant. the two groups will then be compared to one another.


Eligibility criteria:
inclusion criteria: * diagnosis of stroke since at least 6 months prior to recruitment in the study * persistent physical disability due to the stroke * adequate understanding of french exclusion criteria: * significant cognitive impairments * contra-indication of any type to performing physical activity and physical exercise
effectiveness of acupuncture treatment applied in addition to the rehabilitation program in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: the purpose of the study is to assess the effect of acupuncture treatment combinated with conventional rehabilitation methods on gait, fatigue, quality of life and bladder functions in patients with multiple sclerosis

after being informed about study and potential risks, all patient giving written informed consent will undergo screening period determine eligibility for study entry. the patients who meet the eligibility recruitments will get treatment into two groups in a conventional rehabilitation and acupuncture combined with conventional rehabilitation

Eligibility criteria:
inclusion criteria: * being diagnosed with ms according to mcdonald criteria * edss score between 1-6 * the patient is clinically stable * having not had a new ms attack in the last 3 months * being cognitively suitable to participate in the study exclusion criteria: * being clinically unstable * inability to cognitively participate in tests * having received acupuncture treatment in the last 6 months

Keywords: acupuncture gait fatigue